普祺医药港股IPO：“零收入”Biotech的18A背水一战

Core Viewpoint - Puxi Pharmaceutical Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, marking a significant step in its capital journey after withdrawing its application from the Beijing Stock Exchange just three months prior [2][3]. Company Overview - Founded in 2016, Puxi Pharmaceutical focuses on the immune inflammation sector and is recognized as a national-level "specialized and innovative" enterprise. The company positions itself as a leader in localized targeted therapy, with over 60% of its workforce dedicated to research and development [3][8]. - The company has obtained 33 invention patents and achieved a post-investment valuation of 1.806 billion yuan after its latest financing round in December 2024 [3]. Financial Status - Puxi Pharmaceutical has not yet achieved commercial revenue, but it received government subsidies amounting to 112 million yuan and 1.158 million yuan in the first three quarters of 2024 and 2025, respectively [5]. - The company recorded net losses of 178 million yuan and 125 million yuan in the first three quarters of 2024 and 2025, with nearly 80% of its expenditures allocated to research and development [6]. - As of September 2025, the company had cash and cash equivalents of only 155 million yuan, which may not sustain normal operations for a year at the current burn rate [7]. Market Potential - The immune inflammation market is a blue ocean with significant growth potential, being the third-largest chronic disease market globally. The global market for autoimmune disease drugs is expected to reach 217 billion USD by 2033, while the allergic disease market is projected to reach 131.1 billion USD [9]. - In China, the market for these two sectors is expected to grow to 219.6 billion yuan and 293.8 billion yuan by 2033, with over 75 million and 250 million patients suffering from atopic dermatitis and allergic rhinitis, respectively [9]. Product Pipeline - Puxi Pharmaceutical's core product, Pumeixin (PG-011), has completed Phase III clinical trials for its gel formulation for atopic dermatitis and is in Phase III trials for its nasal spray for allergic rhinitis. The company has multiple products in development targeting various conditions, including pruritus, kidney disease, and glaucoma [3][10]. Competitive Advantages - The localized delivery method of Pumeixin is expected to minimize systemic side effects, providing a competitive edge, especially among mild to moderate patients and children [10]. - As a domestic company, Puxi Pharmaceutical has natural advantages in pricing and market access, particularly as it approaches commercialization of its core product [10]. Challenges and Risks - The company faces significant risks, including the uncertainty of regulatory approval for Pumeixin, which has completed Phase III trials but may require additional data for pediatric patients [11]. - Commercialization challenges are also present, as the company lacks a sales team and plans to rely on a Chief Sales Officer (CSO) partnership, which has a low success rate [11]. - Financial pressures are a concern, as the IPO fundraising scale has not been disclosed, and if it falls short of expectations, the company may face cash flow issues [12].